Strategic funding SphingoTec recently closed a €5M Series C financing round led by Think.Health Ventures with continued support from Brandenburg Kapital, HBM Healthcare Investments, NRW.BANK and Wellington Partners, signaling strong investor confidence and potential for scaled partnering and co-development opportunities.

AFIAS expansion The May 2025 commercial launch of the AFIAS sphingotest penKid assay indicates active product roll-out, availability for real-time kidney function assessment, and potential entry points for hospital systems, laboratories, and point-of-care channels.

Clinical focus SphingoTec targets acute medical conditions such as acute heart failure, acute kidney injury and circulatory shock, creating upsell opportunities with cardiology, nephrology, critical care, and emergency medicine customers seeking improved diagnostics and patient management.

Leadership changes Recent leadership transition with the departure of the Managing Director and CFO suggests a potential openness to strategic partnerships, advisory roles, and shared-go-to-market arrangements to accelerate growth and market entry.

Growth trajectory With revenue in the low to mid single digits and a Series C funded for market development, there is a clear path for expanding in high-value hospital networks, diagnostic labs, and regional distributors, leveraging existing investor credibility to secure channel partnerships.